Novel photosensitizer as well as preparation method and application thereof

A photosensitizer, a new type of technology, applied in the field of photosensitizers, can solve problems such as high oxygen dependence, and achieve the effect of outstanding universality and high-efficiency treatment

Pending Publication Date: 2022-04-12
SHANDONG UNIV
4 Cites 0 Cited by

AI-Extracted Technical Summary

Problems solved by technology

[0005] In order to solve the above-mentioned technical problems, the present invention provides a novel photosensitizer and its preparation method and application, so as...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Method used

[0066] Fig. 19 is under normoxia (21%) and hypoxia (1%), with or without light photosensitizer compound IIIa, compound IIc, compound IIIc induces O2- in MCF-7 cells. Dihydroethidium (DHE) was selected as the O2-· detection reagent, and its oxidized product could be inserted into DNA and emit red fluorescence. No matter in normoxia or hypoxia, compounds Ⅲa and Ⅲc can induce the production of O2-· in MCF-7 cells after light irradiation, but compound Ⅱc, a typi...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Abstract

The invention discloses a novel photosensitizer and a preparation method and application thereof, and the preparation method comprises the following steps: adding thionyl chloride into a methanol suspension of D-biotin, stirring overnight at room temperature until a reaction solution is clear and transparent, and carrying out reduced pressure distillation to obtain a white solid; dispersing into methanol, slowly dropwise adding hydrazine hydrate while stirring, heating, and reacting for 10-18 hours; cooling to room temperature, carrying out reduced pressure distillation, pouring methanol, carrying out suction filtration, and washing with methanol for several times to obtain a white powdery compound I; the preparation method comprises the following steps: dissolving a photosensitizer compound II with carboxyl at a terminal in anhydrous DMF in a nitrogen atmosphere, adding EDCI, HOBt and DIEA at 0 DEG C, reacting for 2 hours, adding a compound I, and stirring at room temperature for 24 hours; and performing reduced pressure distillation and purification to obtain a compound III. The novel photosensitizer prepared by the invention can solve the problem of high dependence on oxygen in photodynamic therapy, and has a good treatment effect in both normal oxygen and hypoxic states.

Application Domain

Technology Topic

PhotosensBiotin +10

Image

  • Novel photosensitizer as well as preparation method and application thereof
  • Novel photosensitizer as well as preparation method and application thereof
  • Novel photosensitizer as well as preparation method and application thereof

Examples

  • Experimental program(3)

Example Embodiment

[0044] Example 1
[0045]
[0046] (1) Synthesis of Compound I
[0047]D-biotin (300 mg, 1.23 mmol) of 10 ml of methanol suspension was added to sulfoxide (0.3 mL, 4.0 mmol), stirred at room temperature overnight until the reaction liquid clarified and transparent. The white solid was obtained under reduced pressure. It was dispersed into 10 mL of methanol and slowly dripped the hydrated sac (0.48 mL, 10 mmol) while stirring, heated to 70 ° C, and the reaction was 12 h. Cooled to room temperature, distilled under reduced pressure, poured into a large amount of ice-cold methanol, filtered, washed three times with methanol to give a white powder-shaped compound I.
[0048] (2) Compound IIIA synthesis
[0049] In a nitrogen atmosphere, Compound IIA (DCF-TFM, 20.4 mg, 0.025 mmol) was dissolved in 5 mL anhydrous DMF, 0 ° C, add 1- (3-dimethylaminopropyl) -3-ethyl carbon two Asia Amine hydrochloride (EDCI) (24 mg, 0.125 mmol), 1-hydroxybenzene triazole (HOBT) (17 mg, 0.125 mmol) and N, N-diisopropylidelamine (DIEA) (12.4 μL, 0.075 mmol After 2 h, Compound I (13 mg, 0.05 mmol) was added, and stirred at room temperature for 24 h. Decompression distillation was purified by column chromatography (a system = 1/8 of methanol / dichloromethane). The high distortion of the compound IIIA and the nuclear magnetic resonance spectrum pattern are shown in respectively. figure 1 and figure 2 Indicated.

Example Embodiment

[0050] Example 2
[0051]
[0052] (1) Synthesis of Compound I as in Example 1.
[0053] (2) Synthesis of Compound IIIB
[0054] In a nitrogen atmosphere, compound IIB (Fl, 50 mg, 0.065 mmol) was dissolved in 5 ml of anhydrous DMF, and 1- (3-dimethylaminopropyl) -3-ethyl carbide hydrochloric acid was added at 0 ° C. Salt (EDCI) (62.8 mg, 0.33 mmol), 1-hydroxybenzene triazole (HOBT) (44 mg, 0.33 mmol) and N, N-diisopropylidelamine (DIEA) (32 μL, 0.2 mmol) reaction 2H After the addition, Compound I (33.5 mg, 0.13 mmol) was added, and stirred at room temperature for 24 h. Decompression distillation was purified by column chromatography (methanol / dichloromethane = 1/8) to obtain a photosensitizer compound IIIb. The high distortion of the compound IIIb and the nuclear magnetic resonance spectrometry table show respectively image 3 and Figure 4 Indicated.

Example Embodiment

[0055] Example 3
[0056]
[0057] (1) Synthesis of Compound I as in Example 1.
[0058] (2) Synthesis of Compound IIIC
[0059] In a nitrogen atmosphere, Compound IIC (PPIX, 30 mg, 0.053 mmol) was dissolved in 3 ml anhydrous DMF, and 1- (3-dimethylaminopropyl) -3-ethyl carbide hydrochloric acid was added at 0 ° C. Salt (EDCI) (10.56 mg, 0.053 mmol), 1-hydroxybenzene triazole (HOBT) (7.43 mg, 0.053 mmol) and N, N-diisopropylamine (DIEA) (8.75 μL, 0.053 mmol) After 2 h, Compound I (15.3 mg, 0.05 mmol) was added, and stirred at room temperature for 24 h. Decapression was purified, and the photosensitizer compound was obtained after purification using column chromatography (methanol / dichloromethane = 1/8). The high distortion mass spectrometry of Compound IIIC and the nuclear magnetic resonance spectrum pattern are shown. Figure 5 and Image 6 Indicated.
[0060] Figure 7 For the absorption of photosensitizer compound IIIA and compound IIA in ethanol, Figure 8 For the absorption of photosensitizer compound IIIb and compound IIB in ethanol, Figure 9 The absorption and emission spectrum of the photosensitizer compound III and the compound IIC in ethanol. Such as Figure 7-9 As shown, the absorption and emission spectrum of the photosensitizer compound II and the compound II are almost uniform, and the introduction of biotin does not affect the photophysical properties of the photosensitizer. In particular, compound IIIA has more widely absorbed in the range of 400-700 nm, making it an ideal photosensitizer to capture white light. The maximum emission of compound IIIa can reach 750 nm. At the same time, the introduction of biotin imparts the ability of the compound IIIA to target tumor cells. It can be seen that the compound IIIA has application prospects in the treatment of malignant tumors in near infrared biomatography and image guidance.
[0061] Figure 10 For different photosensitizers in ethanol 1 O 2 Generate rate graph. choose 1 O 2 Temperature 1,3-diphenylisine benofuran (DPBF) 1 O 2 Detection. Record 20MW / cm 2 White (400-800 nm) was irradiated under irradiation, the absorbance at 412 nm decreased over time. As can be seen from the figure, DPBF is almost unchanged under the respective action of compound III and compound II. Note The introduction of biotin does not affect the ability of the photosensitizer single-line oxygen.
[0062] Figure 11 For the photosensitizer compound IIIA, the compound IIa, and the mixture of compound IIA and compound I in the water O 2 -· Produce capacity graph, Figure 12 For the photosensitizer compound IIIb, the compound IIb, and the compound IIb and the mixture of Compound I in the water O 2 -· Produce capacity graph, Figure 13 For the photosensitizer compound IIIC, compound IIC, and compound IIC and compound I of Compound I in the water O 2 -· Generate capacity graph. Select O 2 -· Capture Chloride Nitroquic Tetrazolia (NBT) Perform O 2 -· Detection. Record 20MW / cm 2 Light (400-800 nm) was irradiated under irradiation, the absorbance at 260 nm decreases over time. Compound II in light O 2 -· The production is significantly less than compound III. The results after mixing with the compound II and the compound I is mixed with the individual compound II. 2 -· The ability has little variation, indicating that the active agent covalently modified by biotin is O 2 -· Production has a positive impact. In particular, Compound IIC is a well-known typical type PS compared to compound IIa, compound IIB, and does not have obvious O. 2 -·. Therefore, the compound IIIC's O 2 -· The generation capability should be attributed to the introduction of biotin. This unexpected biotinylation strategy shows that biotinylated photosensitors can have O 2 -· and 1 O 2 The ability to produce, alleviate the dependence of conventional PDT on oxygen.
[0063] Figure 14 and Figure 15 A common focal fluorescence imaging of two cells having different cells of photosensitizer compound IIIA and compound IIa on biotin expression levels, respectively. The results showed that compound III (10 μm) was incubated with biotin receptor negative (COS-7, African green monkey renal source cells) and biotin receptor positive (MCF-7, breast cancer cells) cells, respectively, in the former There is no fluorescence, and the latter has obvious fluorescence in the cell. Compound IIA (10 μm) was incubated with these two cells for 4 h, and fluorescence occurred in both cells. It can be seen that the introduction of biotin imparts the photosensitizer IIIA tumor target.
[0064] Figure 16 For the photosensitizer compound IIIA, in the case of normal oxygen (21%) and lack of oxygen (1%), the dark toxicity map of MCF-7 cells, Figure 17 For the photosensitizer compound IIIA in the case of normal oxygen (21%) and lack of oxygen (1%), the light toxicity of MCF-7 cells. 12W white light (400-800 nm) LED is used in the photodynamic experiment, the optical density is 20mW / cm 2 The illumination time is 10 min. The results showed that under dark conditions, compound IIIA had almost no toxicity to MCF-7, which showed a good biocompatibility of compound IIIA. In light conditions, MCF-7 cells have a significant inhibitory effect. In addition, the inhibition of Tumor cells can still reach more than 50% in the inhibition of tumor cells. This indicates that the compound IIIA's photocyteticity is mainly attributed to other Ros produced under low oxygen conditions. according to Figure 10 The result, other ROS should be O 2 -·. It can be seen that the compound IIIA can effectively relieve the high-degree dependence of photodynamic treatment on oxygen.
[0065] Figure 18 For normal oxygen (21%) and bare oxygen (1%), there is a light-free photo-sensitizer compound IIIA (A), compound IIC (B), compound IIIC (C) to induce an active oxygen in MCF-7 intracellular . Select 2 ', 7'-dichlorocetate (DCFH-DA) as an active oxygen indicator, can be oxidized by ROS to DCF, and green fluorescence is emitted. Under normal oxygen conditions, the fluorescence of DCF was observed, which means that the compound IIIA, compound IIC and compound III in MCF-7 cells can increase the inner ROS level. Even in an oxygen-deficient environment, the obvious fluorescence of DCF is still detected in MCF-7 cells, which highlights the ability of oxygen to produce active oxygen to compound IIIA and compound IIB, and there is no serious effect. In contrast, there is no oxygen substance to produce any active oxygen substance. This means that biochemical photosensitizers provide other ROS rather than just 1 O 2 To kill tumor cells.
[0066] Figure 19 Under normal oxygen (21%) and bare oxygen (1%), there is a light-sensitive photo-sensitive agent compound IIIA, compound IIC, compound IIIC induced MCF-7 intracellular O 2 -· Production situation. Choose dihydrogen ingot (DHE) as O 2 -· Detection reagents, its oxidation product can be inserted into DNA and red fluorescence. Whether it is normal oxygen or lack of oxygen, it can induce MCF-7 intracellular O, ever-borne oxygen. 2 -· The resulting, and typical secondary photosensitizer compound IIC is not available. Indication of biotin's covalent introduction can indeed induce O 2 -· Produce. And O 2 -· It can also be catalyzed by ultravalase (SOD) within the cells, and converted to other high cytotoxic free radicals (such as OH ·) through Haber-WeissS reactions and FENTON reactions. 2 Reuse. This involves O 2 -·The generated one mechanism will provide a more satisfactory efficacy for PDT.
[0067] Figure 20 Explore the mechanism of biotinylation effects, circulating voltammetry as an external standard with ferrocene (Fc). Such as Figure 20 As shown, all three of these three biotinylated photosensitizers exhibit lower reduction potentials than their correspondingly biotinylated photosensitizers. The anode movement of the photosensitizer reduction potential is advantageous to accept electrons, which makes them more likely to produce more O 2 -·.
[0068] The one-type PDT mechanism is as follows:
[0069] 3 Photosensitizer * + Matrix → matrix -· + Photosensitizer -·
[0070] Photosensitizer -· + Oxygen → photosensitizer + O 2 -·
[0071] Such as Figure 21 The configuration shown, the triple state PS is transmitted to oxygen by electron with an electron with an electron with electrons to form O by electrons that receive adjacent substrates and transmitting external electrons to form O 2 -·. According to the results of the theoretical calculations, the folding conformation of Compound IIIA supports a more efficient electron transfer between biotin moieties and PS portions. Therefore, biotin acts as an electron-rich substrate in the manner in the molecule, which facilitates tilting the one-type PDT mechanism.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

no PUM

Description & Claims & Application Information

We can also present the details of the Description, Claims and Application information to help users get a comprehensive understanding of the technical details of the patent, such as background art, summary of invention, brief description of drawings, description of embodiments, and other original content. On the other hand, users can also determine the specific scope of protection of the technology through the list of claims; as well as understand the changes in the life cycle of the technology with the presentation of the patent timeline. Login to view more.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Similar technology patents

Depression therapeutic system on basis of user portrait labels

InactiveCN109793974AGood treatmentSleep inducing/ending devicesPersonalizationUser information
Owner:ZHEJIANG BRAIN ENHANCE TECH CO LTD

Bletilla striata lozenge

ActiveCN107375711AImprove feelingGood treatmentDigestive systemMacromolecular non-active ingredientsAsphyxiaSodium bicarbonate
Owner:贵州盛茂白芨开发有限公司

Detection method of quality cold relief capsule

PendingCN107014911AImproved quality controlGood treatmentComponent separationCalculus bovisHoneysuckle
Owner:吉林修正药业新药开发有限公司

Classification and recommendation of technical efficacy words

  • Good treatment
  • Universal

Medicine for reducing blood lipid

InactiveCN1586574AGood treatmentImprove blood hypercoagulabilityMetabolism disorderUnknown materialsDrugToxicity
Owner:YANGCHUNTANG CHINESE MEDICINE HONGKONG

Compositions and methods for a mycobacterium tuberculosis drug susceptibility test

InactiveUS20140256664A1Good treatmentBiocideOrganic chemistryTuberculomaMycobacterium
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND

Blood pressure reducing pill for hypertension

InactiveCN1586558AGood treatmentImprove blood hypercoagulabilityUnknown materialsPill deliveryHigh Blood PressuresBlood pressure kit
Owner:YANGCHUNTANG CHINESE MEDICINE HONGKONG

Anti-cytokine heterocyclic compounds

ActiveUS20110053955A1Optimized efficacy and pharmacokinetic and safety profileGood treatmentBiocideOrganic chemistryCytokineDisease
Owner:BOEHRINGER INGELHEIM INT GMBH

Single-linear-array laser radar equipment centering method

ActiveCN104483664AInhibiting requirements for high-precision data acquisition and validationUniversalWave based measurement systemsLinear arrayEnvironmental geology
Owner:ACAD OF OPTO ELECTRONICS CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products